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Abstract
Syphilis continues to be an important epidemiologic problem. For a few years a steady increase in the incidence of
this sexually transmitted disease has been observed. Advances in medical science obligate the doctor to use only
such diagnostic and therapeutic approaches that are scientifically proven. Based on the European (IUSTI) and U.S.
(CDC) guidelines, in this manuscript, we present some selected practical issues concerning diagnosis and treatment
of syphilis. We truly hope that the present review will help all doctors taking care of syphilitic patients to system-
atize the current knowledge. 
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Introduction
Syphilis is a sexually transmitted disease found only
in humans, which is caused by a spirochete (Treponema
pallidum). Infection is characterized by a wide sympto-
matology, which makes the diagnosis difficult when based
solely on the clinical picture [1]. The disease continues to
be a significant epidemiological problem [2, 3]. The World
Health Organization estimates that each year in the world
there are about 11 million new cases [4]. Since 2000 in most
European countries and the North America a steady
increase in the incidence of syphilis has been observed [5]. 
Two documents that contain guidelines for diagnosis
and management of patients with syphilis have been
already published. The first one was developed by the
International Union against Sexually Transmitted Infec-
tions (IUSTI, last updated in 2008) [6] and the second one
was developed by the U.S. Centers for Disease Control and
Prevention (CDC, last updated in 2010) [7]. The guidelines
developed by the CDC and IUSTI are not in conflict. 
Advances in medical science obligate doctors to take
only these diagnostic and therapeutic approaches that
have been proven to be effective. The CDC and IUSTI
guidelines are based on scientific research. An appropri-
ate level of evidence was assigned to each therapeutic
approach. It should also be noted that following the guide-
lines is a line of defense in all disputes. 
Diagnosis of syphilis
According to CDC and IUSTI guidelines, blood sero-
logical tests for syphilis (in addition to clinical features)
remain the diagnostic standard. At least one treponemal
antigen test and one non-treponemal antigen test are suf-
ficient to confirm syphilis. The most widely used and rec-
ommended non-treponemal antigen tests (also referred
to as cardiolipin antigen, or non-specific ones) are Vene-
real Disease Research Laboratory (VDRL) and Rapid Plas-
ma Reagin (RPR) [8]. Non-treponemal antigen test results
should be given quantitatively (i.e. titers, for example, 
1 : 16, 1 : 32). It should be emphasized that the titers of
non-treponemal antigen tests correlate with the disease
activity. Non-treponemal test antibody titers should be
also used to assess treatment response. The required
decline in non-treponemal test titers after treatment, com-
pared to baseline, is a marker of the correct response to
the treatment. The VDRL and RPR are equally valid assays,
but quantitative results from the two tests cannot be com-
pared directly. In practice, this means that the non-tre-
ponemal antigen test used to assess treatment response
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should be the same as the one applied for diagnostic pur-
poses. 
Treponemal tests (otherwise referred to as specific
ones) are the second type of diagnostic tests necessary
for the diagnosis of syphilis. Besides ‘classic’ ones, which
are widely used, such as Treponema pallidum haemag-
glutination test (TPHA), Fluorescent Treponemal Antibody
Absorption test (FTA-ABS), Treponema pallidum Particle
Agglutination test (TPPA), there are some new tests – i.e.
immunoassays (Enzyme Immunoassays – EIAs). Most of
EIAs detect total anti-treponemal antibodies (IgG and IgM).
Currently, there are several commercially available kits
such as the ICE Syphilis®, Trepanostica®, Pathozyme
Syphilis®, Enzygnost® Syphilis, Syphilis Bioelisa® and Trep-
Chek®. The sensitivity and specificity of these assays
range between 64% and 95% [9]. All are equally valid. It
is not necessary to verify results of the immunoassays
with other tests. Noteworthy, treponemal test antibody
titers should not be used to assess treatment response.
Capita Syphilis M® is a special immunoassay that detects
IgM antibodies only. It may be used in the diagnosis of
congenital syphilis and early syphilis formerly defined as
‘serum-negative’ (when serological tests are negative). In
cases of such early syphilis, quantitative Capita Syphilis
M® may be used to assess treatment response. 
Both CDC and IUSTI no longer recommend FTA for the
diagnosis of syphilis as being very low specific for Tre-
ponema pallidum [6, 7]. 
Screening tests for syphilis
Treponemal antigen tests, such as TPHA or FTA-ABS,
are currently recommended as screening tests for syphilis.
Such a strategy will identify both persons with previous
treatment for syphilis and persons with untreated or
incompletely treated syphilis. On the other hand, it has
been proven that in the general population, false positive
treponemal tests occur less frequently than false positive
non-treponemal tests. Therefore, in a smaller percentage
of cases it is necessary to verify the diagnosis with non-
treponemal antigen tests. It significantly reduces costs of
the diagnostic procedure [10]. 
Diagnostic scheme
Figure 1 shows a diagnostic scheme recommended by
the CDC and IUSTI (prepared by the authors based on the
recommendations) [6, 7]. Persons with a positive tre-
ponemal test (screening) should have a standard non-tre-
ponemal test with titer (e.g. VDRL). If both tests are pos-
itive, syphilis can be diagnosed. The patient’s medical
history and clinical symptoms should be, however, taken
into account. After the treatment of syphilis, even sever-
al years afterwards, the patient may have positive tre-
ponemal and non-treponemal tests (at low titers). If the
treponemal test (screening) is positive and the non-tre-
ponemal test is negative, then the laboratory should per-
form a different treponemal test (preferably one based on
different antigens than the original test). If the second
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Fig. 1. Syphilis diagnostic scheme
VDRL
TPHA positive
(screening)
FTA-ABS/EIA
Negative
Previously treated syphilis?
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treponemal test is positive, persons with a history of pre-
vious treatment will require no further management
unless sexual history suggests likelihood of re-exposure,
and the patient has no signs and symptoms consistent
with early syphilis (e.g. primary lesion). Patients without
a previous history of treatment for syphilis should be
offered treatment. Unless the history or results of a phys-
ical examination suggest a recent infection, such persons
should be treated for late latent syphilis (see below). 
If the second treponemal test is negative (first tre-
ponemal test positive, second non-treponemal negative),
according to CDC further evaluation or treatment is not
indicated. However, IUSTI recommends a supplementary
confirmatory test in such situation. It should be the IgG
immunoblot test using recombinant antigens (such as
p44, p47, p17, p15). The FTA-ABS may be used as a sup-
plementary test in certain circumstances, e.g. if it has not
been used before as the second treponemal test and the
laboratory is highly specialized with a large volume of con-
firmatory testing, where the quality of reagents and repro-
ducibility of the test can be assured (Figure 1). 
Tests for monitoring the effect of treatment 
Non-treponemal antigen tests, such as VDRL and RPR,
are almost exclusively recommended for monitoring the
serological response to treatment. The titer determined
on a blood specimen taken on the day of treatment gives
the baseline for measuring a decrease in titer. In certain
situations, monitoring after the treatment can be based
on the quantitative test results of Capita Syphilis M®.
Neurosyphilis: a diagnostic challenge
The clinical picture of neurosyphilis has substantially
changed in the past two decades [11]. Nowadays, ‘paral-
ysis progressiva’ and ‘tabes dorsalis’ are seen rarely. Cen-
ters for Disease Control and Prevention (CDC) emphasizes
that more and more cases of neurosyphilis can manifest
as (1) meningitis, (2) ischemic stroke, especially in people
under 40 years of age, (3) rapidly progressive dementia,
especially in young patients, (4) impaired proprioception,
and (5) hearing and sight disturbances, especially unex-
plained uveitis or sudden hearing loss which cannot be
explained otherwise. The European and U.S. guidelines
recommend searching for the above-mentioned neuro-
logical manifestations in patients with syphilis. It is also
highly recommended to perform syphilis testing in
patients being admitted to neurology departments due
to the above-mentioned neurological symptoms. 
No single diagnostic test can be used to diagnose neu-
rosyphilis. The standard serologic test for cerebrospinal
fluid (CSF) is VDRL [7]. Noteworthy, the other non-tre-
ponemal tests such as RPR and USR are not recom-
mended for CSF. It is emphasized that the VDRL in CSF is
highly specific. A positive result, in the absence of CSF
contamination with blood, confirms the diagnosis. How-
ever, a negative result does not exclude neurosyphilis.
CSF-VDRL may be negative in 30–70% of neurosyphilis
cases [12]. Both IUSTI and the CDC highlight that in the
cases of the negative CSF VDRL, other tests should be tak-
en into consideration, such as treponemal assays, CSF cell
count, protein and glucose levels. Treponemal tests per-
formed in CSF (TPHA, FTA-ABS, EIA) are highly sensitive
but nonspecific for the neurosyphilis diagnosis. This
means that the negative results exclude neurosyphilis,
but the positive result does not confirm the diagnosis. The
CSF white cell count cutoff values, which may suggest
neurosyphilis, have been established on the ≥ 5 cells/
mm3 in immunocompetent patients with syphilis and 
≥ 20 cells/mm3 in HIV-positive patients. Neurosyphilis may
be also associated with the CSF protein concentration
higher than 45 mg/dl [13] and the CSF glucose levels of
less than 2.72 mmol/l [14]. So far, there has been no con-
sensus on how many of the above-mentioned additional
criteria must be stated for neurosyphilis diagnosis, when
the CSF VDRL is negative. However, most experts consid-
er that pleocytosis (i.e. elevated CSF cell count) is a nec-
essary condition in all instances. 
Screening for other sexually transmitted 
infections
Both the CDC and IUSTI emphasize that all patients
with a diagnosis of syphilis should be offered: (1) anti-HIV,
(2) anti-HCV, and (3) HbsAg tests. Depending on the time
from the exposure it may reasonable to advise the patient
to repeat the tests after 3 months [6, 7].
Treatment: general remarks
In the experimental studies it has been shown that
a penicillin level of above 0.018 mg/l in blood and CSF
should be considered treponemicidal [15]. Duration of the
treponemicidal level should be at least 7–10 days to cov-
er a number of division times of treponemes. Benzathine
penicillin at a single dose of 2.4 million units provides
a treponemicidal concentration for up to 3–4 weeks (21–
23 days) [16]. Duration of treponemicidal concentration
of procaine penicillin after a single dose is not precisely
defined. There is, however, no doubt that it is significantly
shorter. It has been suggested that it may be even less
than 24 h [6].
Assessing the duration of asymptomatic disease 
Diagnosis of primary and secondary syphilis is based
on clinical features. Latent syphilis is defined as a stage not
accompanied by clinical symptoms but the patient has
a positive serological test. Because of different therapeu-
tic approaches to early latent syphilis and late latent syphilis
it is important to distinguish these two stages of infection.
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It was arbitrarily assumed that early syphilis is an infection
that lasts not longer than a year according to the CDC and
not more than 2 years by IUSTI. Late syphilis is defined as
a disease lasting over 1 or 2 years, respectively. Table 1
shows the criteria required for the diagnosis of early latent
syphilis (prepared by the authors based on the CDC guide-
lines). All patients who (1) do not have at least one criteri-
on specified in Table 1, (2) have positive serological tests in
blood, (3) and do not present clinical symptoms, should be
treated for late latent syphilis.
Syphilis treatment recommendations are based
on the studies of a certain level of evidence 
Each therapeutic recommendation for different stages
of syphilis (i.e. drug regimen, duration of treatment) was
assigned an appropriate level of evidence. Table 2 gives
a brief description of research methodology along with the
associated level of evidence. Randomized controlled trials
have been classified as Ia and Ib. They are considered as the
most reliable ones. 
Treatment of primary, secondary and early latent
syphilis
Table 3 shows the recommended management of pri-
mary, secondary and early latent syphilis. Benzathine
penicillin at a dose of 2.4 million units administered as
a single intramuscular injection remains the treatment
of choice. Noteworthy, alternative medications are rec-
ommended only in cases of penicillin allergy or parenteral
treatment refusal. However, it should be carefully noted
in the patient’s medical record [6]. Data on the efficacy
of ceftriaxone are derived from a single randomized trial
[17]. It should be however stressed that until now, the
optimal dose and duration of ceftriaxone therapy have
not been defined. Moreover, there is a significant cross
reaction between cephalosporins and penicillin. Thus,
using ceftriaxone as an alternative in patients allergic to
penicillin is limited. Efficacy of azithromycin has also been
shown in randomized trials. It was recommended at
a dose of 2 g, given only once, orally [18]. However, intrin-
sic resistance to azithromycin has been described since
2004. Thus, azithromycin is no longer recommended [19]. 
Treatment of late latent syphilis and syphilis 
of unknown duration
Recommended medication for late latent syphilis and
syphilis of unknown duration is shown in Table 4. Ben-
zathine penicillin and procaine penicillin are the first-line
therapies. However, the duration of therapy is longer
when compared to early syphilis. The IUSTI and CDC sug-
gest that in cases of allergy to penicillin, desensitization
should be considered as the evidence base for the use of
non-penicillin regimens, which is relatively weak in late
latent syphilis and syphilis of unknown duration. 
Treatment of tertiary syphilis
Treatment of choice in tertiary syphilis is benzathine
penicillin at a dose of 2.4 million units, given once a week
for 3 consecutive weeks.
Table 1. Criteria required for the diagnosis of early latent syphilis
Positive syphilis blood testing and lack of clinical symptoms
and
documented seroconversion (from negative serologic tests to positive serologic tests)
or
at least 4-fold increase in the non-treponemal test titer, when compared to previous results
or
within the last year based on the patient’s medical history probably he could have clinical symptoms consistent 
with primary or secondary syphilis
or
patient’s sexual partner was treated because of primary, secondary or early latent syphilis
or
based on patient’s medical history, he had exposure (i.e. high risk sexual contacts)
Table 2. Research methodology description and associated
level of evidence
Level of Description
evidence
Ia Meta-analysis of randomized control trials
Ib At least one randomized control trial
IIa At least one well-designed study without
randomization
IIb At least one well-designed quasi-experimental 
study
III At least one well-designed non-experimental
descriptive study
IV Expert committee reports, opinions and/or 
experience 
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Treatment of neurosyphilis
Neurosyphilis may occur both in early and late
syphilis. Table 5 shows the recommended management
of neurosyphilis. The use of non-penicillin regimens is
weak. Thus, in cases of penicillin allergy, desensitization
should be considered. 
Treatment of syphilis in HIV-positive patients
Both the CDC and IUSTI emphasize that until now, there
has been no sufficient scientific evidence to treat HIV co-
infected syphilitic patients otherwise than im munocom-
petent patients [20, 21]. An increased risk of the central
nervous system (CNS) involvement and treatment failure
may occur in patients with HIV who are in significant im -
munosuppression (i.e., CD4 + cell count ≤ 350/µl) [22]. In
these patients, it seems reasonable to perform an imme-
diate lumbar puncture. Further management should be
based on the results of CSF examination. 
Follow-up after treatment
Correct response to treatment is defined as: (1) reso-
lution of clinical symptoms, and (2) at least a 4-fold
decline in the titer of non-treponemal tests (e.g. VDRL),
when compared to baseline: (a) at 6 months after the
treatment (for primary, secondary and early latent
syphilis), (b) within 6–12 months after treatment (for
syphilitic patients with HIV co-infection), or (c) within 12–
24 months after treatment (for late latent syphilis and
syphilis of unknown duration) [6, 7]. Table 6 shows the
recommended (both according to the CDC and IUSTI) fre-
Table 3. Treatment of primary, secondary and early latent syphilis
Drug Dose, administration Treatment duration Level of evidence
Benzathine penicillin 2.4 million units, IM Single dose Ib
Procaine penicillin 600 000 units once daily, IM 10–14 days IIb
Alternatives
Doxycycline 200 mg once daily, PO 14 days III
Tetracycline 500 mg 4× daily, PO 14 days III
Erythromycin 500 mg 4× daily, PO 14 days IV
Azithromycin* 2 g, PO Single dose Ib
Ceftriaxone* 500 mg once daily, IM 10 days Ib
*See the text
Table 4. Treatment of late latent syphilis and syphilis of unknown duration 
Drug Dose, administration Treatment duration Level of evidence
Benzathine penicillin 2.4 million units 1× week, IM 3 consecutive weeks III
Procaine penicillin 600 000 units once daily, IM 17–21 days III
Alternatives
Doxycycline 200 mg once daily, PO 21–28 days IV
Tetracycline 500 mg 4× daily, PO 28 days IV
Erythromycin 500 mg 4× daily, PO 28 days IV
Table 5. Treatment of neurosyphilis
Drug Dose, administration Treatment duration Level of evidence
Crystalline penicillin 12–24 million units daily, 18–21 days (IUSTI) III
3–4 million units every 4 h, I.V. 10–14 days (CDC)
Procaine penicillin 1.2–2.4 million units once daily, 10–17 days (IUSTI) IIb
IM, plus probenecid 500 mg 4× daily, PO 10–14 days (CDC)
Alternatives
Doxycycline 200 mg 2× daily, PO 28 days IV
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When after treatment: 
(1) Persistence of clinical symptoms – group 1
(2) 4-fold increase in titer of non-treponemal test (VDRL, RPR) – group 2
(3) Lack of at least 4-fold decline in titer of non-treponemal at: (a) 6 month after completing the treatment (primary, 
secondary and early latent syphilis), (b) 12-24 month after completing the treatment (late latent syphilis or syphilis of unk-
nown duration) – group 3
a. Primary, secondary and early latent syphilis
CSF examination, and again HIV testing
b. Late latent syphilis and syphilis of unknown duration
CSF examination, again HIV testing and re-treatment (always)*
*Treatment scheme according to CSF examination results
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quency follow-up appointments after treatment for dif-
ferent stages of syphilis. There is no consensus on follow-
up after treatment of tertiary syphilis. It appears, how-
ever, that the follow-up appointments should be more
frequent and take place for a longer period of time.
Inadequate response to treatment is defined as: (1) per-
 sistence of clinical symptoms, (2) 4-fold increase in titer of
the non-treponemal test (e.g. VDRL) and (3) absence of at
least a 4-fold decline in titer of the non-treponemal test
ascertained in certain time periods (defined previously for
different groups of syphilitic patients; see above). Persis-
tence of symptoms (group 1) and a 4-fold increase in titer
of the non-treponemal test (group 2) are almost always
associated with re-infection or treatment failure. Howev-
er, lack of at least a 4-fold decline in titer of the non-tre-
ponemal test may affect as many as 15% of immunocom-
petent patients and may be not linked to re-infection or
treatment failure. Figures 2 A and B (prepared by the
authors based on the guidelines) present the patient care
scheme in cases of inadequate treatment response. To sum
up, almost always re-treatment is indicated. The thera-
peutic scheme (i.e., treatment with penicillin intramuscu-
larly or intravenously) should be chosen according to results
of CSF examination. Noteworthy, there is no consensus on
the management of patients who would not achieve at
least a 4-fold decrease in titer of non-treponemal tests.
Table 6. Frequency of follow-up appointments after completing syphilis treatment 
Months from the treatment end 1 2 3 6 9 12 24
Primary, secondary and early latent syphilis
CDC 2010 X X
IUSTI 2008 X X X X X
Late latent syphilis and syphilis of unknown duration
CDC 2010 X X X
IUSTI 2008 X X X X X X X
”X” means that at this time follow-up appointment is recommended, CDC – Centers for Disease Control and Prevention, IUSTI – International Union against
Sexually Transmitted Infections
Groups 1, 2, 3
treatment as for
neurosyphilis
CSF “negative”
Groups 1, 2
standard
treatment
Group 3?
CSF – cerebrospinal fluid, CSF “positive” – abnormalities in CSF examination consistent with neurosyphilis diagnosis (see the text), CSF “negative” – no CSF
abnormalities or CSF abnormalities not consistent with neurosyphilis diagnosis (see the text)
CSF “positive”
Fig. 2. Patient care scheme in cases of inadequate treatment response 
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Some experts recommend that despite normal results of
CSF examination, re-treatment should be initiated. 
Both IUSTI and CDC note that follow-up after neu-
rosyphilis treatment is based on repeated examination
of CSF. The first follow-up lumbar puncture should be per-
formed 6 months after the end of treatment. The correct
treatment response is considered as a decrease in the
number of white blood cells (WBC) in CSF (i.e. < 5/mm3
in immunocompetent patients and < 20/mm3 in HIV-pos-
itive ones). When the WBC count has not decreased to
the desired value, the treatment must be repeated. Next
CSF examinations should be done after 6 months. 
Diagnosis and treatment of sex partners
Both the CDC and IUSTI particularly stress the impor-
tance of proper diagnosis and management of sexual part-
ners of the patient with syphilis. It has been estimated that
up to 60% of sexual contacts of patients with syphilis may
be infected. A detailed sex history should be taken from the
syphilitic patient with particular reference to persons with
whom the patient had oral, vaginal and anal intercourses
(both with and without protection). Sexual partners of infect-
ed patients should be considered at risk if they have had
sexual contact with the patient within 3 months for patients
diagnosed with primary syphilis. If the infected patient has
been diagnosed as ‘early syphilis’, medical advice should
be given to all sex partners within one year (CDC) or 2 years
(IUSTI). Figure 3 (prepared by the authors based on the
guidelines) presents a sex partner care scheme. It should
be noted that persons exposed within 90 days preceding
the diagnosis of primary, secondary and early latent syphilis
in a sex partner should be treated even if the results of the
clinical and serological examination are negative. Manage-
ment for early syphilis should be initiated.
Conclusions
Syphilis remains to be a serious epidemiological prob-
lem. Advances in medical science obligate doctors to apply
proven effective diagnostic and therapeutic procedures.
Following the guidelines remains the only line of defense
for a doctor in cases of a dispute. Despite a great num-
ber of new treponemal tests, non-treponemal tests are
still very important. Non-treponemal tests are necessary
for the final diagnosis, they are only recommended for
the assessment of treatment response and are of the
highest specificity for the diagnosis of neurosyphilis. Peni-
cillin remains the drug of choice in the treatment of all
forms of syphilis. Diagnosis, treatment, and follow-up of
neurosyphilis are difficult. It is suggested that such
patients should be referred to the tertiary reference cen-
ters. The treatment scheme for syphilitic patients with
HIV co-infection should be the same as for immunocom-
petent patients. Special attention should be paid to the
notification, diagnosis and treatment of sexual partners
of the infected patients.
References
1. Pastuszczak M, Wozniak W, Jaworek A, et al. Pityriasis liche-
noides-like secondary syphilis and neurosyphilis in a HIV
infected patient. Postep Derm Alergol 2013; 30: 127-30. 
2. Karlinska-Jachowska M, Chmielnicki P, Dziankowska-Bart-
kowiak B, et al. Syphilis – issue of the 21st century. Postep
Derm Alergol 2007; 24: 233-7. 
3. Jakubowicz O, Żaba R, Czarnecka-Operacz M. Serological tests
for syphilis performed in the Sexually Transmitted Diseases
Diagnostic Laboratory in Poznań during 2000-2004. Postep
Derm Alergol 2011; 28: 30-5
4. Gerbase AC, Rowley JT, Heymann DH, et al. Global prevalence
and incidence estimates of selected curable STDs. Sex
Transm Infect 1998; 74 (suppl 1): S12-6. 
Last sexual contact? 
Positive
Negative
≤ 90 days
> 90 days
Treatment
Treatment not indicated*
*Clinical examination and syphilis blood testing again after 6 weeks and 3 months
Fig. 3. Sex partner care scheme
Sexual partner of the patient with primary,
secondary or early latent syphilis
Clinical examination
Syphilis blood testing
Postępy Dermatologii i Alergologii 4, August / 2013 210
Maciej Pastuszczak, Anna Wojas-Pelc
5. Fenton KA, Breban R, Vardavas R, et al. Infectious syphilis in
high-income settings in the 21st century. Lancet Infect Dis
2008; 8: 244-53. 
6. French P, Gomberg M, Janier M, et al. IUSTI: 2008 European
Guidelines on the Management of syphilis. Int J STD AIDS
2009; 20: 300-9. 
7. Workowski KA, Berman S. Sexually transmitted diseases
guidelines, 2010. MMWR 2010; 59: 1-116. 
8. Young H. Guidelines for serological testing for syphilis. Sex
Transm Infect 2000; 76: 403-5. 
9 Schmidt BL, EdjlalipourM, Luger A. Comparative evaluation
of nine different enzyme-linked immunosorbent assays for
determination of antibodies against Treponema pallidum in
patinets with primary syphilis. J Clin Microbiol 2000; 38: 
1279-82. 
10. Pope V. Use for treponemal tests to screen for syphilis. Infect
Med 2004; 21: 399-402. 
11. Chahine LM, Khoriaty RN, Tomford WJ, et al. The changing
face of neurosyphilis. Int J Stroke 2011; 6: 136-43.  
12. Golden MR, Marra CM, Holmes KK. Update on syphilis. Resur-
gence of an old problem. JAMA 2003; 11: 1510-4. 
13. Ghanem KG. Neurosyphilis: a historical perspective and
review. CNS Neurosc Ther 2010; 16: e157-68. 
14. Pastuszczak M, Wojas-Pelc A, Jaworek A. Association of CSF
glucose concentration with neurosyphilis diagnosis. Cent 
Eur J Med 2013; 8: 48-51. 
15. Rolfs RT. Treatment of syphilis. Clin Infect Dis 1995; 20 
(Suppl 1): S23-38. 
16. Idsoe O, Guthe T, Willcox RR. Penicillin in the treatment of
syphilis. The experience of three decades. Bull WHO 197; 47:
1-68. 
17. Hook EW, Roddy RR, Handsfield HH. Ceftriaxone therapy for
incubating and early syphilis. J Infect Dis 1988; 158: 881-4. 
18. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromy-
cin versus penicillin G benzathine for the treatment of early
syphilis. N Engl J Med 2005; 353: 1236-44. 
19. Mitchell SJ, Engelman J, Kent CK, et al. Azithromycin resistant
syphilis infection: San Francisco, California, 2000-2004. Clin
Infect Dis 2006; 42: 337-45. 
20. Rompalo AM, Joesoef MR, O’Donnell JA, et al. Clinical mani-
festation of early syphilis by HIV status and gender. Results
of the Syphilis and HIV Study. Sex Transm Dis 1997; 28: 
158-65. 
21. Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial
of enhanced therapy for early syphilis in patients with and
without HIV infection. N Engl J Med 1997; 337: 307-14. 
22. Marra C, Maxwell CL, Smith SL, et al. Cerebrospinal fluid ab-
normalities in patients with syphilis: association with clini-
cal and laboratory features. J Infect Dis 2004; 189: 369-76.
